$66.27 Million in Sales Expected for RTI Surgical, Inc. (RTIX) This Quarter
Analysts expect that RTI Surgical, Inc. (NASDAQ:RTIX) will post sales of $66.27 million for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for RTI Surgical’s earnings, with the lowest sales estimate coming in at $66.25 million and the highest estimate coming in at $66.28 million. RTI Surgical posted sales of $66.55 million in the same quarter last year, which suggests a negative year-over-year growth rate of 0.4%. The business is scheduled to report its next earnings report on Tuesday, October 24th.
On average, analysts expect that RTI Surgical will report full year sales of $66.27 million for the current year, with estimates ranging from $277.80 million to $278.75 million. For the next financial year, analysts forecast that the firm will post sales of $282.01 million per share, with estimates ranging from $281.68 million to $282.33 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that follow RTI Surgical.
RTI Surgical (NASDAQ:RTIX) last issued its quarterly earnings data on Tuesday, August 8th. The medical equipment provider reported $0.02 EPS for the quarter, hitting the consensus estimate of $0.02. RTI Surgical had a negative net margin of 6.53% and a positive return on equity of 2.07%. The firm had revenue of $72.10 million for the quarter, compared to analyst estimates of $70.25 million. RTI Surgical’s quarterly revenue was up 6.7% on a year-over-year basis.
A number of equities analysts recently commented on the company. BidaskClub downgraded RTI Surgical from a “buy” rating to a “hold” rating in a report on Tuesday, August 8th. ValuEngine upgraded RTI Surgical from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. TheStreet upgraded RTI Surgical from a “d+” rating to a “c-” rating in a report on Friday, May 5th. Finally, Zacks Investment Research upgraded RTI Surgical from a “sell” rating to a “hold” rating in a report on Thursday, May 11th.
In related news, Director Nicholas J. Valeriani bought 5,500 shares of the firm’s stock in a transaction on Monday, August 21st. The stock was purchased at an average price of $4.70 per share, with a total value of $25,850.00. Following the completion of the transaction, the director now directly owns 47,754 shares of the company’s stock, valued at $224,443.80. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP John N. Varela bought 12,000 shares of the firm’s stock in a transaction on Friday, August 11th. The shares were bought at an average cost of $4.85 per share, with a total value of $58,200.00. Following the transaction, the executive vice president now directly owns 47,998 shares of the company’s stock, valued at $232,790.30. The disclosure for this purchase can be found here. Corporate insiders own 4.90% of the company’s stock.
Large investors have recently made changes to their positions in the company. Cigna Investments Inc. New bought a new stake in shares of RTI Surgical during the second quarter worth about $105,000. Citigroup Inc. boosted its stake in shares of RTI Surgical by 2,850.1% in the second quarter. Citigroup Inc. now owns 21,152 shares of the medical equipment provider’s stock worth $124,000 after buying an additional 20,435 shares during the last quarter. First Quadrant L P CA bought a new stake in shares of RTI Surgical during the second quarter worth about $137,000. Thompson Davis & CO. Inc. boosted its stake in shares of RTI Surgical by 138.8% in the second quarter. Thompson Davis & CO. Inc. now owns 25,077 shares of the medical equipment provider’s stock worth $147,000 after buying an additional 14,577 shares during the last quarter. Finally, Brandywine Global Investment Management LLC bought a new stake in shares of RTI Surgical during the second quarter worth about $183,000. 68.34% of the stock is owned by hedge funds and other institutional investors.
Shares of RTI Surgical (RTIX) traded down 2.11% during midday trading on Wednesday, reaching $4.65. 141,726 shares of the company traded hands. RTI Surgical has a 12 month low of $2.50 and a 12 month high of $6.00. The stock’s market capitalization is $274.51 million. The company’s 50 day moving average is $5.38 and its 200-day moving average is $4.60.
RTI Surgical Company Profile
RTI Surgical, Inc is engaged in producing orthopedic and other surgical implants that repair and promote the natural healing of human bone and other human tissues. The Company uses natural tissues, metals and synthetics process to produce its products. The Company’s business primarily consists of six categories, such as spine, sports medicine, ortho fixation, bone graft substitutes and general orthopedic (BGS and general orthopedic), dental and surgical specialties.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for RTI Surgical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RTI Surgical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.